Related Experiment Videos
Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer
H Yamamoto1, T Monden, K Ikeda
1Second Department of Surgery, Osaka University Medical School, Japan.
Abstract:
The retinoblastoma gene (Rb gene) is a tumour-suppressor gene and its product (pRB) is known to act as a negative regulator of the cell cycle. Although lack of pRB expression resulting from gene alterations is considered to be responsible for the genesis of several human malignancies, increased expression of pRB has been demonstrated in a majority of colorectal cancer cases. In the present study, we investigated the expression of pRB as well as that of its related kinases, cdk2 and cdc2, in colorectal cancer, since these kinases have been reported to phosphorylate and inactivate pRB. Western blot analysis revealed that colorectal cancer expressed higher levels of cdk2 and cdc2 than did normal mucosa and that the ratio of the hyperphosphorylated form of pRB was higher in colorectal cancer. Furthermore, immunohistochemical studies showed that cdk2/cdc2 was expressed exclusively in the cancer cells positive for pRB. These results suggest that an increase in the expression of cdk2/cdc2 in colorectal cancer may have prevented pRB from braking the cell cycle through phosphorylation.
Insights
Increased retinoblastoma protein (pRB) phosphorylation by elevated cdk2/cdc2 levels in colorectal cancer may drive tumor growth by inhibiting pRB's cell cycle regulation.
Area of Science:
- Oncology
- Molecular Biology
- Cell Cycle Regulation
Background:
- The retinoblastoma gene (Rb gene) product, pRB, is a tumor suppressor that regulates the cell cycle.
- While Rb gene alterations are linked to cancer, elevated pRB expression is observed in many colorectal cancers.
- CDK2 and CDC2 kinases phosphorylate and inactivate pRB.
Purpose of the Study:
- To investigate the expression of pRB and its related kinases, cdk2 and cdc2, in colorectal cancer.
- To understand the role of these kinases in pRB regulation within colorectal tumors.
Main Methods:
- Western blot analysis to quantify protein levels in colorectal cancer and normal tissues.
- Immunohistochemical studies to localize protein expression within tumor cells.
Main Results:
- Colorectal cancer tissues showed higher levels of cdk2 and cdc2 compared to normal mucosa.
- A higher ratio of hyperphosphorylated pRB was found in colorectal cancer.
- cdk2/cdc2 expression was localized to pRB-positive cancer cells.
Conclusions:
- Elevated cdk2/cdc2 expression in colorectal cancer may lead to pRB inactivation.
- This inactivation by phosphorylation could contribute to the loss of cell cycle control in colorectal tumors.
- Further research into targeting these kinases may offer therapeutic strategies for colorectal cancer.